Aims and scope
Molecular Cancer promotes the exchange of ideas, concepts and findings in any area of cancer and related biomedical science, from a molecular point of view. Molecular Cancer is interested in articles from basic, translational and clinical research, opening new avenues for the understanding, prevention, diagnosis and treatment of cancer. Topics of interest include, but are not limited to: cell and tumor biology, angiogenesis, animal models, metastasis, cancer antigens and the immune response to them, cellular signalling and molecular biology, epidemiology, genetic and molecular profiling of cancer and molecular targets, cancer stem cells, DNA damage and repair, cell cycle, apoptosis, molecular virology and vaccine- and antibody-based cancer therapies.
Molecular Cancer provides an important forum for exciting findings in cancer-related research, presenting an unparalleled opportunity to communicate information to specialists and the public. The online appearance of Molecular Cancer allows the immediate publication of accepted articles and the presentation of large amounts of data and supplemental information to ensure that new research is disseminated as efficiently and quickly as possible to the scientific community.
All articles published by Molecular Cancer are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Molecular Cancer you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Molecular Cancer therefore levies an article-processing charge of £1370.00/$2145.00/€1745.00 for each article accepted for publication.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BioMed Central provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
All articles published in Molecular Cancer are included in:
- Biological Abstracts
- Current contents
- PubMed Central
- Science Citation Index Expanded
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Molecular Cancer has an Impact Factor of 6.204.
Peer review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help Editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.
Molecular Cancer operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Submitted manuscripts will be screened for suitability for Molecular Cancer by one of the journal's Editors-in-Chief and appropriate manuscripts will be sent for peer-review. Peer-reviewers are selected by appropriate Associate Editors. Decisions will be made based upon at least two reviewer reports.
All manuscripts submitted to Molecular Cancer should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Citing articles in Molecular Cancer
Articles in Molecular Cancer should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Mol Cancer [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Mol Cancer 2009, 1:115.
Why publish your article in Molecular Cancer
Molecular Cancer's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Molecular Cancer offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Molecular Cancer gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Molecular Cancer are included in article alerts and regular email updates. Some may be highlighted on Molecular Cancer’s pages and on the BioMed Central homepage.
In addition, articles published in Molecular Cancer may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Molecular Cancer. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Molecular Cancer you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.